New drugs for acute kidney injury.

"Declarations Conflicts of interestPP received speaker honoraria from Baxter and advisory board consulting reimbursement from AM-Pharma, EBI, Sphingotec, Adrenomed, 4Teen4. PM received Trial Steering Committee consultancy payments from AM-Pharma. Other consultancy payments: FAST Biomedical, Novartis, Renibus Therapeutics. MO received speaker honoraria from Fresenius Medical Care, Biomerieux, Baxter and Gilead, and research funding from Fresenius Medical Care, Biomerieux, Baxter and LaJolla Pharma and advisory board consultancy reimbursements from AM-Pharma. Conflicts of interest PP received speaker honoraria from Baxter and advisory board consulting reimbursement from AM-Pharma, EBI, Sphingotec, Adrenomed, 4Teen4. PM received Trial Steering Committee consultancy payments from AM-Pharma. Other consultancy payments: FAST Biomedical, Novartis, Renibus Therapeutics. MO received speaker honoraria from Fresenius Medical Care, Biomerieux, Baxter and Gilead, and research funding from Fresenius Medical Care, Biomerieux, Baxter and LaJolla Pharma and advisory board consultancy reimbursements from AM-Pharma."